Apple Watch Launches Non-Invasive Continuous Glucose Monitoring for Pre-Diabetics

Apple has received FDA clearance for a non-invasive continuous glucose monitoring feature in Apple Watch, the company confirmed in a regulatory filing. The capability will roll out as part of the watchOS 14 release in September and will initially focus on pre-diabetes coaching and dietary trend tracking rather than insulin dosing.

How It Works

The sensor sits on the back of the watch alongside the existing optical heart-rate and SpO2 sensors. It uses a combination of near-infrared spectroscopy and a proprietary machine-learning model trained on more than 8 million paired glucose readings to estimate blood glucose levels from interstitial fluid every five minutes. Apple says the readings correlate within 12% of laboratory fingerstick values across the clinically relevant range.

"Continuous glucose monitoring has been life-changing for people with diabetes. Bringing it to a watch millions already wear is the next logical step for preventive health," said Dr. Sumbul Desai, Apple's VP of health.

What's Cleared, What's Not

The FDA cleared the device for trend monitoring and pre-diabetes coaching. It is not cleared for insulin-dose decisions, and the Apple Health app explicitly tells users with diabetes to continue using their prescribed continuous glucose monitor for management. The distinction matters: insulin dosing from a non-invasive device is a higher-risk use case that requires additional clinical evidence.

• Sensor: Non-invasive, on back of watch
• Reading frequency: Every 5 minutes
• Correlation with lab: Within 12% across clinical range
• Indication: Trend tracking, pre-diabetes coaching

Why Pre-Diabetes First

More than 100 million Americans have pre-diabetes, and most are unaware. Continuous feedback on how food and activity affect glucose has been shown to drive meaningful behavioral change in clinical trials. Apple's bet is that giving pre-diabetic users the data earlier — before they progress to type 2 diabetes — will be both clinically valuable and commercially large. Insurers including Aetna and UnitedHealthcare have already announced coverage for the feature.

A clearance for use in insulin dosing decisions is expected to follow within 18 months, after Apple collects additional clinical data. For now, the feature represents the most ambitious consumer-health expansion the Apple Watch has made since its launch.